Blood disorders including leukemia and lymphoma can be cured with unrelated donor (URD) hematopoietic cell transplantation (HCT) and cord blood transplantation (CBT). Post-transplant complications and mortality may be lowered through comprehensive HLA matching of the stem cell source. KIR-HLA interactions further define transplant outcome. The clinical practice of URD HCT and CBT today has several unmet needs. HLA identity of the URD does not guarantee that the patient will not develop life-threatening post-transplant complications, indicating the presence of undetected MHC region variation. For patients who lack matched URDs, the rules that govern permissible HLA mismatches are needed so as to broaden the availability of HCT to all patients in need. In CBT, the relevance of undetected disparity at HLA-A, B, C, DR, and DQ is unknown. Natural killer (NK)-mediated effects may further modulate transplant risks. Overall, clinical outcome is inferior for patients of non-Caucasian ethnicity. This project has two major goals. First, we will define the clinical importance of MHC residue variation after URD HCT and CBT by measuring the impact of HLA mismatching in non-Caucasian populations, identifying non-permissible HLA mismatches, and novel MHC resident genes. Second, we will define the clinical impact of KIR-HLA interactions, determine the molecular mechanisms underlying donor NK alloreactivity through a systematic evaluation of activating KIRs and haplotypes, and define mechanisms involved for the development of NK alloreactivity. These research questions will address the current roadblocks in URD HCT and CBT and provide novel laboratory-based information that can be translated to clinical practice for all patients of diverse racial background.
(provided by applicant: Even though blood disorders such as leukemia and lymphoma can be cured through transplantation of stem cells from a healthy unrelated donor or cord blood stem cells, patients suffer from life-threatening complications. The risks of complications after transplantation are caused by variation in the genetic code between the patient and the stem cells. This project will find the genes that are causing the complications so that the information may be used to select unrelated donors and cord blood stem cells that lower risks. In this way, patients can be cured of their cancer and live longer healthier lives.
|Boudreau, Jeanette E; Giglio, Fabio; Gooley, Ted A et al. (2017) KIR3DL1/ HL A-B Subtypes Govern Acute Myelogenous Leukemia Relapse After Hematopoietic Cell Transplantation. J Clin Oncol 35:2268-2278|
|Petersdorf, E W (2017) In celebration of Ruggero Ceppellini: HLA in transplantation. HLA 89:71-76|
|Petersdorf, Effie W (2016) Mismatched unrelated donor transplantation. Semin Hematol 53:230-236|
|Boudreau, Jeanette E; Mulrooney, Tiernan J; Le Luduec, Jean-Benoît et al. (2016) KIR3DL1 and HLA-B Density and Binding Calibrate NK Education and Response to HIV. J Immunol 196:3398-410|
|Mulrooney, Tiernan J; Zhang, Aaron C; Goldgur, Yehuda et al. (2015) KIR3DS1-Specific D0 Domain Polymorphisms Disrupt KIR3DL1 Surface Expression and HLA Binding. J Immunol 195:1242-50|
|Petersdorf, Effie W; Malkki, Mari; O'hUigin, Colm et al. (2015) High HLA-DP Expression and Graft-versus-Host Disease. N Engl J Med 373:599-609|
|Tarek, N; Gallagher, M M; Chou, J F et al. (2015) KIR and HLA genotypes have no identifiable role in single-unit dominance following double-unit umbilical cord blood transplantation. Bone Marrow Transplant 50:150-2|
|Sobecks, Ronald M; Wang, Tao; Askar, Medhat et al. (2015) Impact of KIR and HLA Genotypes on Outcomes after Reduced-Intensity Conditioning Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 21:1589-96|
|Petersdorf, Effie W (2015) HLA mismatching in transplantation. Blood 125:1058-9|
|Boudreau, Jeanette E; Le Luduec, Jean-Benoît; Hsu, Katharine C (2014) Development of a novel multiplex PCR assay to detect functional subtypes of KIR3DL1 alleles. PLoS One 9:e99543|
Showing the most recent 10 out of 34 publications